Pharma's Almanac TV
PA TV
Dashboard
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Research
CDMO
CRO
Excipients
Pharmaceutical Equipment
Pharmaceutical Intermediates
Supply Chain Logistics
Magazine
Current Issue
Archive
Community
Company A to Z
Content Filter
More+
Staffing
Media Kit
By The Numbers
Asthma
12 Articles Available
Can't find what you're looking for? Try our
advanced search
.
Licensing
LEO Pharma Enters License Agreement with Oneness Biotech and Microbio Shanghai for FB825 a Novel Atopic Dermatitis and Asthma Drug Candidate
PR-M04-20-NI-023
GSK's Asthma Biologic Approved
PR-M04-20-NI-007
Clinical Trials
Sosei Heptares Notes the Announcement of Positive Results from Phase III IRIDIUM Study of Inhaled Combination QVM149 in Patients with Uncontrolled Asthma
PR-M10-19-NI-011
Asthma
Asthma Patients in Europe Will Have Access to a Self-Administered Syringe
PAO-M08-19-NI-031
Asthma
GSK Has Hopes for Trelegy in Asthma
PAO-M05-19-NI-011
Market Prediction
Global $1.82 Billion Asthma Spacers Market Outlook, 2026
PR-M04-19-NI-083
Clinical Study
Pulmatrix to Present Results from the Pulmazole (PUR1900) Phase 1/1b Study at 2018 Annual Scientific Meeting
PR-M11-18-NI-063
FDA Approval
FDA Approves Asthma Indication for Dupixent® (dupilumab)
PR-M10-18-NI-090
Breakthrough Therapy
Breakthrough Therapy Designation for New Asthma Drug
PAO-M09-18-NI-008
Approval
European Commission Expands Marketing Approval for GSK’s Relvar Ellipta
PAO-M03-18-NI-013
FDA Approval
AstraZeneca’s Anti-Asthma FASENRA Wins FDA Approval
PAO-M11-17-NI-038
Clinical Trials
GSK and Innoviva Present Positive Results from Pioneering Asthma Study
PAO-M09-17-NI-020
